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Abstract
Background: Proteolytic cleavage of the extracellular domain (EpEx) of Epithelial cell adhesion molecule (EpCAM) and 
nuclear signaling by its intracellular oncogenic domain Ep-ICD has recently been implicated in increased proliferation 
of cancer cells. The clinical significance of Ep-ICD in human tumors remains an enigma.
Methods: EpEx, Ep-ICD and β-catenin immunohistochemistry using specific antibodies was conducted on 58 archived 
thyroid cancer (TC) tissue blocks from 34 patients and correlated with survival analysis of these patients for up to 17 
years.
Results: The anaplastic (ATC) and aggressive thyroid cancers showed loss of EpEx and increased nuclear and 
cytoplasmic accumulation of Ep-ICD. In contrast, the low grade papillary thyroid cancers (PTC) showed membranous 
EpEx and no detectable nuclear Ep-ICD. The ATC also showed concomitant nuclear expression of Ep-ICD and β-
catenin. Kaplan-Meier Survival analysis revealed reduced overall survival (OS) for TC patients showing nuclear Ep-ICD 
expression or loss of membranous EpEx (p < 0.0004), median OS = 5 months as compared to 198 months for patients 
who did not show nuclear Ep-ICD or demonstrated only membranous EpE.
Conclusion: We report reciprocal loss of membrane EpEx but increased nuclear and cytoplasmic accumulation of Ep-
ICD in aggressive TC; nuclear Ep-ICD correlated with poor OS of TC patients. Thus nuclear Ep-ICD localization may serve 
as a useful biomarker for aggressive TC and may represent a novel diagnostic, prognostic and therapeutic target for 
aggressive TC.
Background
Epithelial cell adhesion molecule (EpCAM) is a 40kDa
transmembrane glycoprotein frequently overexpressed
in human malignancies, normal stem and progenitor
cells, cancer-initiating cells in breast, colon, pancreas
and prostate carcinomas and albeit at lower levels in
normal epithelia [1-11]. There is a large database on
EpCAM staining for many cancers and normal tissues.
However, all these studies used antibodies directed
against the extracellular domain (EpEx) of EpCAM that
detected the EpCAM precursor or cell-bound EpEx, or
both [3]. EpCAM serves important roles in cell adhe-
sion, proliferation, differentiation, migration, cell cycle
regulation and is implicated in cancer and stem cell
signaling [12].
Regulated intramembrane proteolysis has recently been
shown to act as the mitogenic signal transducer of
EpCAM in vitro and in vivo [13]. The cleavage and shed-
ding of EpCAM ectodomain, EpEx, by proteases- TACE
and Presenilin-2, has been shown to release its intracellu-
lar domain (Ep-ICD) that translocates to the nucleus. The
association of Ep-ICD with FHL2 and Wnt pathway com-
ponents - β-catenin and Lef-1 forms a nuclear complex
that binds DNA at Lef-1 consensus sites and induces gene
transcription, leading to increased cell proliferation and
has been shown to be oncogenic in immunodeficient
mice [13]. In view of the novel role of EpCAM as an onco-
genic signal transducer and cancer stem cell marker
[12,14-16], it is important to establish the clinical signifi-
cance of nuclear Ep-ICD in human cancers. Nuclear Ep-
ICD was recently reported in a preliminary study in
human colon cancer, but not in the normal colonic epi-
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thelium [13]. In view of the tremendous heterogeneity in
solid tumors, the clinical significance of nuclear Ep-ICD
in other human cancers needs to be established.
Thyroid cancer (TC) represents 90% of all endocrine
malignancies with an estimated annual incidence of
122,800 cases worldwide and approximately 33,000
newly diagnosed cases in USA [17]. Anaplastic thyroid
cancer (ATC) is a rare but very aggressive form of this
malignancy, accounting for less than 2% of all TC. ATC
commonly presents as a rapidly increasing neck mass
that spreads locally, compresses the adjacent structures,
with a tendency to disseminate to regional lymph nodes
and distant sites [18,19]. Most well differentiated TC
have an excellent prognosis, with relative 5-year survival
rates above 95%, despite their tendency for early metas-
tasis. However, the less-differentiated thyroid tumors -
ATC and other aggressive metastatic TC can be fatal
with median survival time ranging from 4 months to 5
years [19]. This variation in clinical outcomes remains a
major challenge that may be attributed to the differ-
ences in genetic damage acquired by the aggressive and
non-aggressive TC during their malignant evolution
[20-22].
β-Catenin plays important roles in cell adhesion and
signal transduction [23]. β-Catenin associates with E-
cadherin and α-catenin linking the adherens junctions
and cytoskeleton, besides acting as a mediator of tran-
scription through DNA-binding proteins, such as TCF/
LEF family members in the nucleus [24]. Loss of mem-
brane-associated β-catenin and a relative increase in
cytosolic or nuclear expression, has been reported in ana-
plastic and poorly differentiated TCs and in thyroid papil-
lary microcarcinoma [25-27]. β-catenin -RET kinase
pathway has been shown to be a critical contributor to
the development and metastasis of human thyroid carci-
noma [28]. Immunohistochemical analysis of EpEx (using
the monoclonal antibody 17-1A directed against extracel-
lular domain of EpCAM) showed membrane staining in
differentiated TC and poorly differentiated TC. In con-
trast the ATC completely lacked EpEx expression [29]. In
view of the aggressive nature of ATC these findings are
puzzling. To address this challenge we sought to investi-
gate EpEx and Ep-ICD protein expression in human pri-
mary TC by immunohistochemistry (IHC) using
antibodies directed against Ep-Ex and Ep-ICD domains of
EpCAM.
Further, concurrent staining for nuclear β-catenin was
carried out to establish its correlation with the oncogenic
Ep-ICD signaling in TC. To our knowledge our study is
the first report demonstrating the clinical relevance of
nuclear Ep-ICD and its putative utility as an adverse
prognosticator in human TC.
Methods
Patients and tissue specimens
The study was approved by Mount Sinai Hospital
Research Ethics Board, T oronto, Canada. Fifty eight TC
formalin fixed paraffin embedded (FFPE) tissue blocks
obtained from 34 patients were retrieved from the
archives of the Department of Pathology, Mount Sinai
Hospital, Toronto, Canada. Each case was reviewed by
the pathologist prior to further experiments. The TC
blocks analyzed included- 19 ATC, 4 insular carcinomas
(poorly differentiated), 1 poorly differentiated papillary
thyroid cancer (PDPTC), 1 poorly differentiated follicular
thyroid cancer (PDFTC), 24 PTC, 3 FTC, 4 squamous cell
carcinoma (SCC) and 2 normal thyroid tissues. The
patient follow up data were retrieved from the clinical
data base of one of us (PGW) to correlate the protein
expression in tumors with clinical outcome to evaluate
the prognostic relevance of these proteins. The patients
were followed up for a minimum period of 15 months and
a maximum period of 17 years.
Antibodies
Anti human-EpCAM mouse monoclonal antibody
MOC-31(AbD Serotec, Oxford, UK) recognizes an extra-
cellular component (EGF1 domain- aa 27-59) in the
amino-terminal region of EpCAM [30]. Intracellular
domain of EpCAM, α-EpICD antibody 1144 [Epitomics
Inc. (Burlingame, CA)] recognizes the cytoplasmic
domain of human EpCAM. β-catenin antibody was raised
against aa 571-781 of β-catenin (Cat.# 610154, B D Sci-
ences, San Jose, CA).
Immunohistochemistry for EpEx and Ep-ICD expression in 
thyroid cancers
Serial TC tissue sections (4 μm thickness) were deparaf-
finized, hydrated in xylene and graded alcohol series. The
slides were treated with 0.3% H2O2 at room temperature
for 30 minutes to block the endogenous peroxidase activ-
ity. After blocking the non-specific binding with normal
horse or goat serum, the sections were incubated with
anti human antibodies -EpEx mouse monoclonal anti-
body MOC-31 (dilution 1:200), or α- EpICD rabbit
monoclonal antibody 1144 (dilution 1:200), or mouse
monoclonal β-catenin antibody (dilution 1:200) for 30
minutes and biotinylated secondary antibody (horse anti-
mouse or goat anti-rabbit) for 30 minutes. The sections
were finally incubated with VECTASTAIN Elite ABC
Reagent (Vector laboratories, Burlington, Ontario, Can-
ada) and diaminobenzedine was used as the chromogen.
Evaluation of immunohistochemical staining
Immunopositive staining was evaluated in five areas of
the tissue sections as described [31]. Sections were scoredRalhan et al. BMC Cancer 2010, 10:331
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as positive if epithelial cells showed immunopositivity in
the plasma membrane, cytoplasm, and/or nucleus when
observed by two evaluators who were blinded to the clin-
ical outcome. These sections were scored as follows: 0, <
10% cells; 1, 10-30% cells; 2, 30-50% cells; 3, 50-70% cells;
and 4, >70% cells showed immunoreactivity. Sections
were also scored semi-quantitatively on the basis of
intensity as follows: 0, none; 1, mild; 2, moderate; and 3,
intense. Finally, a total score (ranging from 0 to 7) was
obtained by adding the scores of percentage positivity
and intensity for each of the thyroid cancer and normal
thyroid tissue sections. The immunohistochemical data
were subjected to statistical analysis as described previ-
ously [31]. The immunohistochemical scoring data were
verified using the Visiopharm Integrator System (Visiop-
harm, Horsholm, Denmark). Only the nuclear staining
was quantitated, as the software did not permit simulta-
neous quantitation of membranous, cytoplasmic and
nuclear staining based on differences in intensity of posi-
tive brown staining.
Statistical analysis
The immunohistochemical data were subjected to statis-
tical analysis using SPSS 10.0 software (SPSS Inc., Chi-
cago, IL). Box plots were used to determine the
distribution of total score of membranous EpEx, nuclear
Ep-ICD and nuclear or cytoplasmic β-catenin expression
in normal thyroid tissues and thyroid cancers. A cut-off =
or > 2 was defined as positive criterion for nuclear β-
catenin immunopositivity for statistical examination. For
membranous β-catenin, score of 6 was defined as loss of
expression. The correlation between expression of EpEx,
Ep-ICD and/or β-catenin staining with overall patient
survival was evaluated using life tables constructed from
survival data with Kaplan- Meier plots.
Results
Immunohistochemical Analysis of EpEx and Ep-ICD 
expression in Thyroid Cancer
To determine the clinical significance of Ep-Ex and Ep-
ICD in TC, their expressions were analyzed in archived
tissues by immunohistochemistry using domain specific
antibodies against EpEx (MOC-31) and Ep-ICD (1144)
respectively. The immunostaining scores of EpEx, Ep-
ICD, and beta-catenin in individual tissue sections are
given in Table 1. No plasma membrane EpEx immunore-
activity was observed in ATC (Fig. 1, panel IA); intense
nuclear and cytoplasmic Ep-ICD immunostaining was
observed in ATC (Fig. 1, panel IIA). β-catenin immunos-
taining was carried out in serial sections to determine if
there was any correlation between cytoplasmic/nuclear
Ep-ICD and nuclear/cytoplasmic β-catenin. Our study
showed concurrent cytoplasmic and nuclear β-catenin
immunostaining in ATC (Fig. 1, panel IIIA). In compari-
son, a subset of the poorly differentiated follicular TC
(PDFTC) showed moderate Ep-ICD cytoplasmic and
nuclear staining (Fig. 1panel IIB); predominant mem-
brane and mild cytoplasmic staining was observed for β-
catenin (Fig. 1, panel IIIB). The PDPTC showed EpEx
membrane staining (Fig. 1, panel IC); Ep-ICD staining
was detected in some tumor nuclei and less intense cyto-
plasmic immunoreactivity was also observed in these
tumors (Fig. 1, panel IIC); in comparison only membrane
and mild cytoplasmic β-catenin staining was observed
(Fig. 1, panel IIIC). The well differentiated PTC
(WDPTC) showed intense EpEx membrane staining (Fig.
1, panel ID) but no Ep-ICD nuclear staining and only
mild cytoplasmic immunostaining was observed in these
tumors (Fig. 1, panel IID) and only intense membrane
staining was observed for β-catenin (Fig. 1, panel IIID). In
comparison the normal (non-malignant) thyroid tissues
showed basal membrane EpEx immunoreactivity (Fig. 1,
panel IE), faint or absent cytoplasmic/nuclear Ep-ICD
staining (Fig. 1, panel IIE) and basal membrane immu-
nostaining for β-catenin (Fig. 1, panel IIIE). The
squamous cell carcinoma variant showed faint EpEx
membrane immunoreactivity (Fig. 1, panel IF); intense
cytoplasmic and nuclear Ep-ICD staining (Fig. 1, panel
IIF); and membranous and cytoplasmic immunoreactiv-
ity for β-catenin (Fig. 1, panel IIIF). The symbols M, C, N
refer to membrane, cytoplasmic and nuclear localization
of the protein.
Illustrated in Fig. 2 is a pattern of differential expression
of these proteins in different regions of an ATC tumor
with varying degrees of aggressive tumor pathology. The
panel AI depicts an ATC section showing no EpEx mem-
brane staining, while the panel AII shows intense nuclear
and cytoplasmic localization of Ep-ICD in the serial ATC
section and panel AIII shows membrane, cytoplasmic
and nuclear β-catenin expression. Another tissue block
from the same patient showed SCC - Panel BI shows focal
faint membrane EpCAM expression, while Panel BII
shows intense nuclear and cytoplasmic Ep-ICD staining
and Panel BIII shows nuclear and membranous β-catenin
expression. In comparison another tissue block from the
same patient showing features of PDFTC as demon-
strated by only membranous EpEx (Panel CI) and only
cytoplasmic Ep-ICD was observed (Panel CII) and mem-
branous and cytoplasmic β-catenin was observed (Panel
CIII). The adjacent normal thyroid tissue from this
patient showed membranous EpEx staining (Panel DI)
without Ep-ICD nuclear staining (Panel DII) and only
membranous staining for β-catenin (Panel DIII). These
different staining patterns observed in the same patient
support the influence of different subcellular expressionRalhan et al. BMC Cancer 2010, 10:331
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Figure 1 Immunohistochemical analysis of EpEx, Ep-ICD and β catenin in thyroid cancer. The ATC did not show detectable membranous EpEx 
staining (IA); all the other subtypes of TC analyzed and normal thyroid tissues showed varying levels of plasma membranous EpEx staining (IB-IF). Nu-
clear Ep-ICD staining was observed in undifferentiated and poorly differentiated TC (IIA-IIC, and IIF), but not in well differentiated TC and the adjacent 
normal thyroid tissue (IID, IIE). Correlated with nuclear Ep-ICD staining, nuclear or cytoplasmic β catenin staining was observed in aggressive TC (IIIA-
IIIC, and IIIF), while membranous staining was observed in the less aggressive TC and the adjacent normal thyroid tissues (IIID, IIIE). Panels A, B and F- 
I and II, C and F III- original magnification × 40; panels A III, B III, C, D, E - I and II, D and E III- original magnification × 20. The abbreviations M, C, and N 
denote membranous, cytoplasmic and nuclear localization of the proteins.
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Table 1: IHC Scoring of EpEx, Ep-ICD and β-catenin in Thyroid cancers
S No. Subtype EpEx EpEx EpEx Ep-ICD Ep-ICD EP-ICD β-catenin β-catenin β-catenin
MCN M C N M C N
1 N o r m a l 760 0 5 0 7 5 0
2 N o r m a l 760 0 6 0 6 4 0
3 P T C 740 3 5 0 5 4 0
4 P T C 750 5 5 0 5 0 0
5 P T C 740 0 5 0 6 5 0
6 P T C 750 0 6 0 6 6 0
7 P T C 750 0 5 3 7 3 0
8 P T C 630 3 6 0 6 5 0
9 P T C 760 0 4 0 4 3 0
1 0 P T C 760 4 5 0 7 0 0
1 1 P T C 750 0 7 0 7 5 0
1 2 P T C 750 0 6 0 7 5 0
1 3 P T C 760 0 5 0 7 5 0
1 4 P T C 750 2 5 0 5 0 0
1 5 P T C 740 0 5 0 5 2 0
1 6 P T C 650 2 5 0 5 0 0
1 7 P T C 640 0 4 0 5 0 0
1 8 P T C 750 3 6 0 7 3 0
1 9 P T C 760 4 5 0 6 4 0
2 0 P T C 750 0 6 0 7 6 0
2 1 P T C 760 0 6 0 7 5 0
2 2 P T C 760 3 6 0 7 6 0
2 3 P T C 740 0 6 0 4 4 0
2 4 P T C 640 0 5 0 3 2 0
2 5 P T C 640 0 6 0 6 4 0
2 6 P T C 750 0 5 0 7 6 0
2 7 F T C 650 0 5 0 7 2 0
2 8 F T C 230 7 3 0 7 3 0
2 9 F T C 650 0 4 0 7 6 0
3 0 P D P T C750 0 6 2 6 5 0
3 1 P D F T C750 2 5 2 6 5 0
3 2 S C C 220 0 5 4 5 4 0
3 3 S C C 320 0 5 0 5 4 0
3 4 S C C 430 0 5 3 5 4 0
3 5 S C C 530 0 5 4 5 4 0
3 6 I n s u l a r000 3 4 0 0 0 0
3 7 I n s u l a r000 5 4 0 0 0 0
3 8 I n s u l a r750 5 5 2 6 4 0
3 9 I n s u l a r740 0 5 0 7 6 0
4 0 A T C 000 0 5 6 2 6 0
4 1 A T C 000 0 5 6 0 2 3
4 2 A T C 000 0 3 7 0 2 0
4 3 A T C 000 0 2 2 0 0 0Ralhan et al. BMC Cancer 2010, 10:331
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patterns which correlate with varying degrees of aggres-
sive pathology in different subsets of TC.
Box-Plot analysis
The distribution of total immunostaining scores of EpEx,
Ep-ICD and β-catenin, determined in sections of normal
thyroid tissues and different subtypes of TC are shown in
Figures 3, 4, 5. The nuclear Ep-ICD staining was quanti-
fied using the Visiopharm Integrator System; the histo-
gram showing percentage nuclear Ep-ICD positivity in all
the different subtypes of TC is given in Fig. 6. The ATC,
insular, PDPTC and PDFTC analyzed showed nuclear Ep-
ICD expression, the total nuclear Ep-ICD positive area
ranged from 12- 40%, while the PTC did not show nuclear
expression. Overall, analysis of β-catenin expression in
different subtypes of TC showed predominantly cytoplas-
mic expression though some nuclear expression was also
observed in ATC. In comparison, membrane localization
of β-catenin was observed in most of the PDFTC, PDPTC
and WDPTC (except for a small subset) as well as in the
non-malignant thyroid tissues.
Correlation of Ep-ICD and EpEx expression with disease 
outcome
Kaplan-Meier Survival analysis of the 34 TC patients in
this study revealed reduced overall survival (OS) for
patients showing nuclear Ep-ICD expression (p < 0.0004,
Fig. 7A). The median OS was 5 months in patients show-
ing nuclear Ep-ICD as compared to 198 months for
patients who did not. Further, patients showing loss of
membranous EpEx also had shorter OS (median = 5
months) than those showing membranous expression
(median = 198 months, p < 0.0004, Fig. 7B).
Discussion
The key findings of our study are: (i) The ATC showed
loss of membrane EpEx, but increased Ep-ICD accumula-
tion in cytoplasm and nucleus of tumor cells. These
tumors also showed concomitant nuclear β catenin
expression. Our observations strongly suggest that Ep-
ICD may be acting as an oncogenic signal transducer in
these tumors by activation of Wnt pathway components
including β catenin to promote rapid growth of these
tumors and a poor prognosis; (ii) EpEx membrane over-
expression was observed in both well differentiated- folli-
cular and papillary TC, where as only a small subset of
poorly differentiated- follicular and papillary TC showed
nuclear Ep-ICD localization. (iii) TC patients showing
nuclear Ep-ICD expression or loss of membranous EpEx
showed reduced OS (p < 0.0004, median OS = 5 months
as compared to 198 months for patients who did not
show nuclear Ep-ICD or showed membranous EpEx).
Interestingly, our study is the first report using an anti-
body specific for the cytoplasmic domain of Ep-ICD that
demonstrates its cytoplasmic and nuclear accumulation
in ATC. The regulated intramembrane proteolysis (RIP)
of EpCAM has recently been proposed to produce Ep-
ICD that has been shown to transduce EpCAM signaling
in cancer cells and activate Wnt proteins-resulting in
increased nuclear accumulation of β-catenin and the tar-
get genes - c-myc and cyclinD1[13].
Demonstration of concomitant nuclear expression of
Ep-ICD and β-catenin in ATC supports the hypothesis
that activation of Ep-ICD signaling also increased the
Wnt pathway component activation and could account
for the increased oncogenic signaling in ATC. β-catenin
plays an important role as a signaling factor involved in
4 4 A T C 000 0 2 7 0 2 0
4 5 A T C 000 0 3 3 5 2 0
4 6 A T C 000 0 0 2 2 4 0
4 7 A T C 000 0 3 5 3 4 0
4 8 A T C 000 0 2 2 0 0 0
4 9 A T C 000 0 5 4 3 5 0
5 0 A T C 000 0 5 5 0 5 5
5 1 A T C 000 0 5 6 0 4 5
5 2 A T C 000 0 5 5 0 2 2
5 3 A T C 000 0 4 5 0 4 4
5 4 A T C 000 0 4 4 0 3 3
5 5 A T C 000 0 4 4 3 4 2
5 6 A T C 000 0 5 3 0 2 2
5 7 A T C 000 0 4 4 5 6 4
5 8 A T C 750 6 5 2 0 0 0
Table 1: IHC Scoring of EpEx, Ep-ICD and β-catenin in Thyroid cancers (Continued)Ralhan et al. BMC Cancer 2010, 10:331
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canonical Wnt pathway [32]. Nuclear localization of β-
catenin is involved in precancerous change in oral leuko-
plakia [33], and is known to associate with malignant
transformation of human cancers including colorectal,
gastric and esophageal tumors [34-37]. The activation of
canonical Wnt signaling pathway results in nuclear trans-
location of β-catenin [38]. Hence nuclear β-catenin is a
marker for active cell proliferation. In contrast to mem-
branous and cytoplasmic expression, nuclear localization
of β-catenin is implicated in tumor progression. The
nuclear β-catenin expression in ATC also supports the
aggressive nature of such tumors.
Most remarkably, the survival analysis data showed a
correlation between nuclear Ep-ICD accumulation and
reduced OS of TC patients (p < 0.0004). Further, loss of
membranous E pEx also correlated with reduced OS of
TC patients (p < 0.0004), OS (median = 5 months) as
compared to those TC patients who did not show nuclear
accumulation of these proteins (median = 198 months).
However, to our knowledge this is the first report under-
scoring the clinical significance of nuclear Ep-ICD as an
adverse prognosticator for aggressive TC. Although the
numbers of ATC analyzed in our study is small, our novel
observations on the clinical correlation of Ep-ICD
nuclear localization as an oncogenic signal of TC appears
to be a quite striking and consistent finding to date.
Our observations of loss of EpEx expression on the
plasma membrane of A T C is in accord with an earlier
Figure 2 Differential immunohistochemical expression of EpEx, Ep-ICD and β-catenin proteins in different regions of an ATC tumor with 
varying degrees of aggressive tumor pathology. No membranous EpEx staining was observed in the ATC tissue section (IA), faint membranous 
EpEx staining in tissue section showing squamous cell carcinoma (IB), membranous EpEx staining in both poorly differentiated TC section and the 
adjacent normal thyroid tissue section (IC, ID). Nuclear and cytoplasmic Ep-ICD staining in undifferentiated and poorly differentiated TC tissue sections 
(IIA-IIC), membranous and cytoplasmic staining in the adjacent thyroid normal tissue (IID). Nuclear and cytoplasmic β catenin staining in ATC section 
(IIIA), membranous β catenin staining in different regions of this tumor with varying degrees of aggressive tumor pathology (IIIB-IIID). A-D, original 
magnification × 10.
EpEx (MOC31) Ep-ICD (1144) -catenin
PDFTC
Normal
I II III
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report on EpCAM expression in TC by Ensinger et al.,
[29]. Our results using MOC-31, an antibody that recog-
nizes the extracellular domain of Ep-CAM, also confirm
the surprising loss of EpCAM expression from the plasma
membrane in ATC. There are numerous reports in the
literature on the cell membrane expression of EpCAM in
TC and other human cancers [8-10,29,30,39-43], leading
to the suggestion that it could be an ideal candidate for
application as a cancer marker and a therapeutic target.
However, the loss of membrane EpEx and the increased
nuclear and cytoplasmic localization of Ep-ICD in ATC
and other aggressive TC suggest that another therapeutic
approach targeting Ep-ICD is likely to be more effective
in the treatment of such aggressive TC.
Conclusions
In conclusion, we demonstrate loss of membranous EpEx
and increased nuclear and cytoplasmic accumulation of
Ep-ICD in a selected subset of aggressive TC (ATC and
some PDPTC and PDFTC). A concomitant increase in
nuclear β-catenin in these aggressive carcinomas suggests
Figure 3 Box-Plot analysis of EpEx expression in thyroid cancers. 
Box plots showing distribution of total immunostaining scores deter-
mined by immunohistochemistry in paraffin-embedded sections of 
normal thyroid tissues and different types of thyroid cancers. The ver-
tical axis gives the total immunostaining score, obtained as described 
in the Methods section. Upper panel depicts the membranous EpEx lo-
calization in normal tissues and PTC, no detectable expression in ATC 
and varying reduced expressions in Insular, FTC and SCC (with a medi-
an score of 3, bold horizontal line). The lower panel depicts cytoplas-
mic EpEx localization in normal tissues, PTC, PDPTC, PDFTC, insular and 
FTC, no detectable expression in ATC and varying reduced expression 
in SCC. No detectable nuclear EpEx staining was observed in normal 
tissues, or in any of the subtypes of TC, hence this box plot was not in-
cluded in the figure.
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Figure 4 Box-Plot analysis of Ep-ICD expression in thyroid can-
cers. The upper panel shows box plots for membranous Ep-ICD local-
ization in normal tissues, some PTC, insular, PDFTC and PDPTC, but no 
membranous staining in ATC, FTC and SCC. The middle panel depicts 
cytoplasmic Ep-ICD localization in normal tissues, PTC, ATC, FTC, insular 
and SCC, PDPTC and PDFTC. The lower panel depicts nuclear Ep-ICD 
localization in ATC and varying expression in SCC, (with a median score 
of 3, bold horizontal line, range 0-4, as shown by vertical bars), as com-
pared to PTC, insular, FTC, PDPTC, PDFTC and normal thyroid tissues 
with a median score of 0.
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a pathogenic role of Wnt signaling in these malignancies.
F u r t h e r ,  e i t h e r  l o s s  o f  m e m b r a n o u s  E p E x ,  o r  n u c l e a r
accumulation of Ep-ICD correlated with poor OS of such
TC patients. We propose that nuclear Ep-ICD may serve
as a putative biomarker for aggressive TC and functions
as a potential target for novel diagnostic, prognostic and
therapeutic strategies in the management of aggressive
TC.
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Figure 5 Box-Plot analysis of β-catenin expression in thyroid can-
cers. The upper panel shows box plots for membranous β-catenin 
staining in ATC only. The middle panel shows cytoplasmic β-catenin in 
all the subtypes of TC analyzed. The lower panel shows nuclear β-
catenin in normal tissues and all the subtypes of TC analyzed except 
most of the ATCs.
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Figure 6 Ep-ICD nuclear staining in different subtypes of thyroid 
cancers using the Visiopharm Integrator System. Representative 
histogram showing nuclear Ep-ICD expression in ATC, PDPTC and PD-
FTC analyzed, while no nuclear Ep-ICD accumulation was observed in 
the PTCs or the normal thyroid tissues analyzed.
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Figure 7 Kaplan-Meier estimation of cumulative proportion of 
overall survival: (A) Nuclear Ep-ICD accumulation in thyroid can-
cers correlated significantly with reduced overall survival (OS) of 
these patients (p < 0.0004). The median OS was 5 months in the 
group of patients showing nuclear Ep-ICD as compared to 198 months 
for patients who did not have detectable nuclear Ep-ICD. (B) Loss of 
membranous EpEx expression was also associated with reduced over-
all survival (OS) for patients. The patients showing loss of membranous 
EpEx had shorter OS (median = 5months) than those showing mem-
branous expression (median = 198 months, p < 0.0004).
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